Compare TEX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | PTGX |
|---|---|---|
| Founded | 1933 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.4B |
| IPO Year | 1994 | 2016 |
| Metric | TEX | PTGX |
|---|---|---|
| Price | $63.89 | $110.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $68.80 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.0M | 507.7K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $47.67 | $874.25 |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | ★ N/A | $2,195.80 |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $49.86 |
| 52 Week High | $71.50 | $111.45 |
| Indicator | TEX | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 61.85 |
| Support Level | $58.36 | $94.48 |
| Resistance Level | $65.64 | N/A |
| Average True Range (ATR) | 2.45 | 4.80 |
| MACD | 0.44 | 1.33 |
| Stochastic Oscillator | 80.34 | 90.91 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.